(Q38633453)

5 September 2017

Response of patients with refractory myasthenia gravis to rituximab: a retrospective study (English)

1 reference

5 September 2017

0 references

1 reference

Richard J Nowak

1

1 reference

5 September 2017

Daniel B Dicapua

series ordinal

2

1 reference

5 September 2017

Nazlee Zebardast

series ordinal

3

1 reference

5 September 2017

Jonathan M Goldstein

series ordinal

4

1 reference

5 September 2017

1 September 2011

1 reference

Therapeutic advances in neurological disorders

5 September 2017

1 reference

5 September 2017

4

1 reference

5 September 2017

5

1 reference

5 September 2017

259-266

1 reference

Rituximab in autoimmune hematologic diseases: not just a matter of B cells

5 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Rituximab in the management of refractory myasthenia gravis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Rituximab in non-haematological disorders of adults and its mode of action

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Rituximab for myasthenia gravis: three case reports and review of the literature

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Current and future standards in treatment of myasthenia gravis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Invited article: inhibition of B cell functions: implications for neurology

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Steroids and immunosuppressant drugs in myasthenia gravis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

B-cell targeting: a novel approach to immune intervention today and tomorrow

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Myasthenia gravis: past, present, and future

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Successful treatment of refractory generalized myasthenia gravis with rituximab

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3187675

[Loss of CD20 expression following rituximab-combined chemotherapy in CD20-positive and CyclinD1-positive multiple myeloma]

31 August 2018

1 reference

PubMed

12 December 2020

Rituximab in refractory MuSK antibody myasthenia gravis

1 reference

PubMed

12 December 2020

Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756285611411503

1 reference

release_2zb7n4hbzbfxlbhpbirjpztxpi

5 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2zb7n4hbzbfxlbhpbirjpztxpi

24 November 2022

mapped directly with Wikidata item

1 reference

5 September 2017

PubMed publication ID

22010039

1 reference